{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pneumococcal+13-valent+Conjugate+Vaccine&page=2",
    "query": {
      "intervention": "Pneumococcal 13-valent Conjugate Vaccine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 94,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pneumococcal+13-valent+Conjugate+Vaccine&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pneumococcal+13-valent+Conjugate+Vaccine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T04:33:52.634Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00574548",
      "title": "Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Vaccines"
      ],
      "interventions": [
        {
          "name": "13 valent Pneumococcal Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "23-valent Pneumococcal Polysaccharide Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Wyeth is now a wholly owned subsidiary of Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "60 Years to 64 Years"
      },
      "enrollment_count": 720,
      "start_date": "2007-11",
      "completion_date": "2010-02",
      "has_results": true,
      "last_update_posted_date": "2011-07-22",
      "last_synced_at": "2026-10-08T04:33:52.634Z",
      "location_count": 6,
      "location_summary": "Chandler, Arizona • Pembroke Pines, Florida • Boise, Idaho + 3 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00574548"
    },
    {
      "nct_id": "NCT02518555",
      "title": "Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Pneumococcal 13-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Jennifer Woyach",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2016-01-12",
      "completion_date": "2026-01-05",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-10-08T04:33:52.634Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02518555"
    },
    {
      "nct_id": "NCT04745559",
      "title": "Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diffuse Large-Cell Lymphoma",
        "Primary Mediastinal Large B-Cell Lymphoma (PMBCL)",
        "Transformed Follicular Lymphoma (TFL)",
        "High-grade B-cell Lymphoma (HGBCL)",
        "Follicular Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pneumococcal conjugate vaccine (PCV13)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CD19 targeted CAR T Cell Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2021-02-18",
      "completion_date": "2027-06",
      "has_results": true,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-08T04:33:52.634Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04745559"
    },
    {
      "nct_id": "NCT02987972",
      "title": "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "V114 Lot 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "V114 Lot 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13™",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Weeks",
        "maximum_age": "12 Weeks",
        "sex": "ALL",
        "summary": "6 Weeks to 12 Weeks"
      },
      "enrollment_count": 1051,
      "start_date": "2017-03-21",
      "completion_date": "2018-10-04",
      "has_results": true,
      "last_update_posted_date": "2019-10-23",
      "last_synced_at": "2026-10-08T04:33:52.634Z",
      "location_count": 30,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 27 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Palmdale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02987972"
    },
    {
      "nct_id": "NCT02184572",
      "title": "Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Measles; Mumps; Rubella",
        "Measles-Mumps-Rubella Vaccine"
      ],
      "interventions": [
        {
          "name": "Priorix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "M-M-R II",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Varivax",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Havrix",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 1742,
      "start_date": "2014-08-25",
      "completion_date": "2015-12-22",
      "has_results": true,
      "last_update_posted_date": "2021-01-07",
      "last_synced_at": "2026-10-08T04:33:52.634Z",
      "location_count": 80,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 69 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02184572"
    },
    {
      "nct_id": "NCT04379713",
      "title": "20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pneumococcal Disease"
      ],
      "interventions": [
        {
          "name": "20-valent pneumococcal conjugate vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "13-valent pneumococcal conjugate vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "42 Days",
        "maximum_age": "98 Days",
        "sex": "ALL",
        "summary": "42 Days to 98 Days"
      },
      "enrollment_count": 1511,
      "start_date": "2020-05-21",
      "completion_date": "2022-08-31",
      "has_results": true,
      "last_update_posted_date": "2023-06-13",
      "last_synced_at": "2026-10-08T04:33:52.634Z",
      "location_count": 41,
      "location_summary": "Tucson, Arizona • Fullerton, California • Oxnard, California + 33 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Ventura",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04379713"
    },
    {
      "nct_id": "NCT03439657",
      "title": "Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Herpes Zoster"
      ],
      "interventions": [
        {
          "name": "HZ/su vaccine GSK1437173A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevenar13",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 913,
      "start_date": "2018-04-12",
      "completion_date": "2020-03-03",
      "has_results": true,
      "last_update_posted_date": "2022-01-11",
      "last_synced_at": "2026-10-08T04:33:52.634Z",
      "location_count": 3,
      "location_summary": "Marlborough, Massachusetts • Salisbury, North Carolina • Spartanburg, South Carolina",
      "locations": [
        {
          "city": "Marlborough",
          "state": "Massachusetts"
        },
        {
          "city": "Salisbury",
          "state": "North Carolina"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03439657"
    },
    {
      "nct_id": "NCT06740630",
      "title": "A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chickenpox"
      ],
      "interventions": [
        {
          "name": "Investigational varicella vaccine_Lot 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational varicella vaccine_Lot 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational varicella vaccine_Lot 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Marketed varicella vaccine_Lot 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Marketed varicella vaccine_Lot 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hepatitis A vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV (pneumococcal conjugate vaccine) 13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PCV 20",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vaxneuvance",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "15 Months",
        "sex": "ALL",
        "summary": "12 Months to 15 Months"
      },
      "enrollment_count": 1840,
      "start_date": "2025-01-10",
      "completion_date": "2027-05-17",
      "has_results": false,
      "last_update_posted_date": "2026-05-29",
      "last_synced_at": "2026-10-08T04:33:52.634Z",
      "location_count": 59,
      "location_summary": "Mobile, Alabama • Hot Springs, Arkansas • Sherwood, Arkansas + 50 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Sherwood",
          "state": "Arkansas"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06740630"
    },
    {
      "nct_id": "NCT05170399",
      "title": "Vaccine Responses in Patients With B Cell Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "AREXVY, ABRYSVO",
          "type": "DRUG"
        },
        {
          "name": "PREVNAR 20",
          "type": "DRUG"
        },
        {
          "name": "PNEUMOVAX 23",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Heplisav -B",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PREVNAR 13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Shingrix",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 350,
      "start_date": "2022-09-14",
      "completion_date": "2036-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-10-08T04:33:52.634Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05170399"
    },
    {
      "nct_id": "NCT03313037",
      "title": "Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pneumococcal Infections"
      ],
      "interventions": [
        {
          "name": "Multivalent",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Prevnar 13",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PPSV23",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "60 Years to 64 Years"
      },
      "enrollment_count": 444,
      "start_date": "2017-10-10",
      "completion_date": "2018-12-10",
      "has_results": true,
      "last_update_posted_date": "2019-12-26",
      "last_synced_at": "2026-10-08T04:33:52.634Z",
      "location_count": 14,
      "location_summary": "Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03313037"
    }
  ]
}